Azurity Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AZURITY, and when can generic versions of AZURITY drugs launch?
AZURITY has thirty-two approved drugs.
There are eighty-six US patents protecting AZURITY drugs.
There are three hundred and forty patent family members on AZURITY drugs in forty-eight countries and forty-one supplementary protection certificates in fifteen countries.
Summary for Azurity
| International Patents: | 340 |
| US Patents: | 86 |
| Tradenames: | 31 |
| Ingredients: | 24 |
| NDAs: | 32 |
| Patent Litigation for Azurity: | See patent lawsuits for Azurity |
Drugs and US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | NYMALIZE | nimodipine | SOLUTION;ORAL | 203340-002 | Apr 8, 2020 | RX | Yes | Yes | 11,207,306 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Azurity | KONVOMEP | omeprazole; sodium bicarbonate | FOR SUSPENSION;ORAL | 213593-001 | Aug 30, 2022 | RX | Yes | Yes | 11,771,686 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Azurity | EPANED KIT | enalapril maleate | FOR SOLUTION;ORAL | 204308-001 | Aug 13, 2013 | DISCN | Yes | No | 9,968,553 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Azurity | ZONISADE | zonisamide | SUSPENSION;ORAL | 214273-001 | Jul 15, 2022 | RX | Yes | Yes | 11,478,456 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | RX | Yes | No | 8,026,279 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Azurity | ERYTHROMYCIN | erythromycin | TABLET;ORAL | 061621-002 | Approved Prior to Jan 1, 1982 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-002 | Feb 25, 2011 | 5,583,141 | ⤷ Try a Trial |
| Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-001 | Feb 25, 2011 | 5,958,961 | ⤷ Try a Trial |
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-004 | Jan 30, 2019 | 10,130,580 | ⤷ Try a Trial |
| Azurity | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | 5,583,141 | ⤷ Try a Trial |
| Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | 5,179,189 | ⤷ Try a Trial |
| Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | 4,757,128 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AZURITY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2018-08-31 |
| ➤ Subscribe | Powder for Oral Solution | 1 mg/mL | ➤ Subscribe | 2016-06-21 |
International Patents for Azurity Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 546381 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2008123536 | ⤷ Try a Trial |
| European Patent Office | 2614814 | ⤷ Try a Trial |
| Argentina | 047972 | ⤷ Try a Trial |
| Japan | 4216713 | ⤷ Try a Trial |
| Israel | 165687 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Azurity Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1718641 | C 2012 017 | Romania | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL SI SARURI ACCEPTABILE FARMACEUTICALE ACESTUIA, INCLUZAND SAREA DEUTHORISATION: 20111207; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/ POTASIU; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/734/001 - RO EU/1/11/734/011; DATE OF NATIONAL A734/001 - EMEA EU/1/11/734/011; DATE OF FIRST AUTHORISATION IN EEA: 20111207 |
| 1718641 | 121 5004-2012 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/735/011 20111207 |
| 1718641 | C20120004 00052 | Estonia | ⤷ Try a Trial | PRODUCT NAME: EDARBI - ASILSARTAANMEDOKSOMIIL;REG NO/DATE: C(2011) 9280 FINAL 07.12.2011 |
| 1718641 | C01718641/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL; REGISTRATION NO/DATE: SWISSMEDIC 62158 31.08.2012 |
| 1507558 | C300528 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705 |
| 0443983 | 2007C/043 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
